Dren Bio is a privately held, clinical-stage biopharmaceutical company based in San Carlos, California, developing first-in-class antibody therapeutics that selectively deplete pathogenic cells for the treatment of cancer, autoimmune and other serious diseases. Its lead program, dibotatug (DR-01), a CD94-targeting monoclonal antibody, is in late-stage development for rare blood cancers including cytotoxic T-cell lymphoma and large granular lymphocytic leukemia, as well as autoimmune diseases. The company also advances a broader pipeline from its proprietary Targeted Myeloid Engager and Phagocytosis Platform; platform program DR-0201 (SAR448501) was acquired by Sanofi in 2025 and Dren Bio received the 2025 Prix Galien USA Award for Best Biotech Startup.
1
Round
1
Industry
5
Tags
Oct 29, 2026
Latest raise
Funding activity · 1 round
Oct 29, 2026
$350M
Series C+
Led by Lightspeed Venture Partners
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
